The Impact of Psycholeptic Reduction on Residential Aged Care Facility

Total Page:16

File Type:pdf, Size:1020Kb

The Impact of Psycholeptic Reduction on Residential Aged Care Facility The impact of psycholeptic reduction on residential aged care facility residents by Daniel Jake Hoyle BPharm (Hons) BCGP School of Pharmacy and Pharmacology | University of Tasmania Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy University of Tasmania November, 2020 Declaration of originality This thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain any material that infringes copyright. Name: Daniel Hoyle Signed: Dated: 17/02/2020 Authority of access This thesis may be available for loan and limited copying and communication in accordance with the Copyright Act 1968. Name: Daniel Hoyle Signed: Dated: 17/02/2020 ii | Page Daniel J. Hoyle Statement of ethical conduct The research associated with this thesis abides by the international and Australian codes on human and animal experimentation, the guidelines by the Australian Government's Office of the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety Committees of the University. Ethics Approval Number H0013999. Name: Daniel Hoyle Signed: Dated: 17/02/2020 Statement regarding published work contained in thesis Chapter 4 has been modified from a published paper. The publisher of that paper holds the copyright for that content and access to the material should be sought from the respective journal. The remaining non-published content of the thesis may be available for loan and limited copying and communication in accordance with the Copyright Act 1968. Name: Daniel Hoyle Signed: Dated: 17/02/2020 Statement of co-authorship Given that this thesis contains work that has been published, a statement of co-authorship is provided for each chapter that includes published work. The following people and institutions contributed to the publication of work undertaken as part of this thesis: iii | Page Daniel J. Hoyle Candidate: Daniel J. Hoyle1 Author 1: Juanita L. Breen2 Author 2: Ivan K. Bindoff1 Author 3: Lisa M. Clinnick3 Author 4: Aidan D. Bindoff2 Author 5: Gregory M. Peterson1 1School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Private Bag 26, Hobart, TAS 7001 2Wicking Dementia Research & Education Centre, College of Health and Medicine, University of Tasmania, Private Bag 143, Hobart, TAS 7001 3Aged Operations, Ballarat Health Services Contribution of work by co-authors for each paper: PAPER 1: Incorporated into Chapter 4 Hoyle DJ, Bindoff IK, Clinnick LM, Peterson GM, Westbury JL. Clinical and economic outcomes of interventions to reduce antipsychotic and benzodiazepine use within nursing homes: a systematic review. Drugs & Aging. 2018;35(2):123-34. Author contributions: Candidate acted as the corresponding author and contributed towards conception and design of the systematic review; data extraction and synthesis; data analysis and interpretation; and writing the manuscript. Authors 1, 2, 3 and 5 contributed towards the conception and design of the systematic review; data analysis and interpretation; and revising the manuscript critically for intellectual content. iv | Page Daniel J. Hoyle PAPER 2: Incorporated into Chapter 6 Hoyle DJ, Peterson GM, Bindoff IK, Clinnick LM, Bindoff AD, Breen JL. Clinical impact of antipsychotic and benzodiazepine reduction: findings from a multicomponent psychotropic reduction program within long-term aged care. International Psychogeriatrics. 2020; Under review. Candidate is acting as the corresponding author and contributed to the conception and design of the study; data collection; data analysis and interpretation; and writing the manuscript. Authors 1, 2, 3 and 5 contributed towards the conception and design of the study; data analysis and interpretation; and revising the manuscript critically for intellectual content. Author 4 provided statistical support and reviewed the manuscript critically for intellectual content. We, the undersigned, endorse the above stated contribution of work undertaken for each of the published (or submitted) peer-reviewed manuscripts contributing to this thesis: Signed: Daniel Hoyle Dr Juanita Breen Associate Professor Candidate Primary Supervisor Glenn Jacobson School of Pharmacy and Wicking Dementia Research Head of School Pharmacology & Education Centre School of Pharmacy and University of Tasmania University of Tasmania Pharmacology University of Tasmania Date: 29/01/2020 29/01/2020 03/02/2020 v | Page Daniel J. Hoyle Abstract Introduction Antipsychotics and benzodiazepines, collectively known as psycholeptics, are widely used in residential aged care facilities (RACFs), leading to concern that residents are being inappropriately sedated. Whilst antipsychotics are clinically appropriate for severe psychiatric illnesses (e.g., bipolar disorder, schizophrenia), they are often used long-term for neuropsychiatric symptoms, particularly in residents with dementia. Benzodiazepines are typically used for insomnia, anxiety, and acute agitation. Considering evidence of only modest efficacy for these indications and the risk of severe adverse effects, guidelines generally recommend reserving these medications for scenarios where non-pharmacological measures are ineffective and/or where there is a risk of harm or severe distress to the resident or others. Benzodiazepines, in particular, are not recommended for neuropsychiatric symptoms in people with dementia. If used, antipsychotics should be reviewed and reduced at a minimum of six to 12 weeks, depending on the country, and the use of benzodiazepines should be limited to a maximum of two to four weeks. Despite these recommendations, prolonged and widespread use suggests that these medications are not being reviewed and reduced regularly. Many interventions have, to varying degrees of success, reduced the use of these medications in RACFs. However, clinical outcomes for the RACF residents and staff, and the economic impact of these interventions are rarely reported (see Chapter 4). Concern of potential deterioration in resident symptoms resulting in increased workloads is one of the reasons for a lack of willingness to reduce these medications. Therefore, to address these gaps in the literature and minimise perceived barriers to sedative reduction, the focus of this thesis was to evaluate the impact that antipsychotic and benzodiazepine dose reduction had on resident- and RACF staff-related outcomes and health vi | Page Daniel J. Hoyle care costs within RACFs involved in a multicomponent program to improve antipsychotic and benzodiazepine use. Methods The national expansion of the ‘Reducing Use of Sedatives’ (RedUSe) program involved 150 Australian RACFs. The main components of RedUSe comprised two quality improvement cycles incorporating auditing and benchmarking of prescribing, education, and multidisciplinary sedative reviews. The program was implemented between March 2014 and April 2016. A prospective, observational, longitudinal study design was utilised to investigate outcomes related to changes in antipsychotic and/or benzodiazepine doses between baseline and four months among residents of a convenience sample of 28 RACFs involved in RedUSe between January 2015 and March 2016. Resident-related outcomes Permanent residents (n=206) taking antipsychotics and/or benzodiazepines on a daily basis, who did not have a severe psychiatric illness (where antipsychotic therapy should generally be maintained long-term e.g., bipolar disorder, schizophrenia) and were not considered end-stage palliative, were recruited. Neuropsychiatric symptoms (Neuropsychiatric Inventory-Nursing Home version (NPI-NH) and Cohen-Mansfield Agitation Inventory (CMAI)), quality of life (QoL; Assessment of Quality of Life-4D (AQoL-4D)), social withdrawal (Multidimensional Observation Scale for Elderly Subjects (MOSES)-withdrawal subscale) and activities of daily living (Physical Self-Maintenance Scale (PSMS)) were assessed at baseline and four months by nursing staff who completed psychometric tests as proxy raters. Lastly, the number and severity of falls and behavioural events, number and reason for general practitioner (GP) consultations and number, length and reason for hospitalisations of vii | Page Daniel J. Hoyle recruited residents were recorded by the nursing staff between baseline and four months. Figure 1 illustrates all data collection associated with this project. Staff-related outcomes The occupational disruptiveness of the neuropsychiatric symptoms was assessed at baseline and four months during psychometric testing with the NPI-NH. Additionally, a survey of job satisfaction (adjusted-Measure of Job Satisfaction) was made available to all RACF nurses and carers for anonymous completion at baseline and four months (Figure 1). Basic costing analysis Health care utilisation costs were estimated using the cost of prescribed medications at baseline and four months, and the estimated cost of GP consultations and hospitalisations between baseline and four months. Statistical methodology Considering the longitudinal design, analyses were restricted to residents who were followed up at baseline and four months. Associations between changes in the NPI-NH (total, factor and occupational disruptiveness scores), CMAI (total and factor
Recommended publications
  • RUNNING HEAD: Anomalous Experiences and Hypnotic Suggestibility
    Anomalous experiences and hypnotic suggestibility 1 RUNNING HEAD: Anomalous experiences and hypnotic suggestibility Anomalous experiences are more prevalent among highly suggestible individuals who are also highly dissociative David Acunzo1, Etzel Cardeña2, & Devin B. Terhune3* 1 Centre for Mind/Brain Sciences, University of Trento, Rovereto, Italy 2 Department of Psychology, Lund University, Lund, Sweden 3 Department of Psychology, Goldsmiths, University of London, London, UK * Correspondence address: Devin B. Terhune Department of Psychology Goldsmiths, University of London 8 Lewisham Way New Cross, London, UK SE14 6NW [email protected] Word count: 3,186 The data that support the findings of this study are openly available in Open Science Framework at osf.io/cfa3r. Anomalous experiences and hypnotic suggestibility 2 Abstract Introduction: Predictive coding models propose that high hypnotic suggestibility confers a predisposition to hallucinate due to an elevated propensity to weight perceptual beliefs (priors) over sensory evidence. Multiple lines of research corroborate this prediction and demonstrate a link between hypnotic suggestibility and proneness to anomalous perceptual states. However, such effects might be moderated by dissociative tendencies, which seem to account for heterogeneity in high hypnotic suggestibility. We tested the prediction that the prevalence of anomalous experiences would be greater among highly suggestible individuals who are also highly dissociative. Methods: We compared high and low dissociative highly suggestible participants and low suggestible controls on multiple psychometric measures of anomalous experiences. Results: High dissociative highly suggestible participants reliably reported greater anomalous experiences than low dissociative highly suggestible participants and low suggestible controls, who did not significantly differ from each other. Conclusions: These results suggest a greater predisposition to experience anomalous perceptual states among high dissociative highly suggestible individuals.
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacol Ther
    NIH Public Access Author Manuscript Pharmacol Ther. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Ther. 2009 August ; 123(2): 239±254. doi:10.1016/j.pharmthera.2009.04.002. Ethnobotany as a Pharmacological Research Tool and Recent Developments in CNS-active Natural Products from Ethnobotanical Sources Will C. McClatcheya,*, Gail B. Mahadyb, Bradley C. Bennettc, Laura Shielsa, and Valentina Savod a Department of Botany, University of Hawaìi at Manoa, Honolulu, HI 96822, U.S.A b Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, U.S.A c Department of Biological Sciences, Florida International University, Miami, FL 33199, U.S.A d Dipartimento di Biologia dì Roma Trè, Viale Marconi, 446, 00146, Rome, Italy Abstract The science of ethnobotany is reviewed in light of its multidisciplinary contributions to natural product research for the development of pharmaceuticals and pharmacological tools. Some of the issues reviewed involve ethical and cultural perspectives of healthcare and medicinal plants. While these are not usually part of the discussion of pharmacology, cultural concerns potentially provide both challenges and insight for field and laboratory researchers. Plant evolutionary issues are also considered as they relate to development of plant chemistry and accessing this through ethnobotanical methods. The discussion includes presentation of a range of CNS-active medicinal plants that have been recently examined in the field, laboratory and/or clinic. Each of these plants is used to illustrate one or more aspects about the valuable roles of ethnobotany in pharmacological research.
    [Show full text]
  • An FAQ Explaining the Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly
    Pharmacy Quality Measures An FAQ Explaining the Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly by Natalie Bari WHERE DOES THIS MEASURE sures feature medications from the the diagnoses (such as insomnia, agi- FIT INTO THE OVERALL MEDI- American Geriatrics Society’s Beers tation, delirium) that the Beers Criteria CARE PART D STAR RATINGS? Criteria for potentially inappropriate state should be avoided. This measure was endorsed by the medication use in older adults. The Pharmacy Quality Alliance (PQA) original HRM measure discussed the WHAT DOES THIS MEASURE in May 2014. But to date, it has not use of non-benzodiazepine sedative ANALYZE? been adopted by the Medicare Part D hypnotics, but it did not include This measure calculates the percent of Star Ratings program. The measure benzodiazepines as they were listed as patients 65 years of age and older who is often described as an extension “avoid only for treatment of insomnia, have received two or more prescription of the PQA measure on the use of agitation or delirium.” The additional fills for any benzodiazepine sedative high-risk medications in the elderly measure was created to address the hypnotic for a cumulative period of (HRM), which was used in the calcu- concern that an unintended conse- more than 90 days. The benzodiaze- lation of the CMS 2015 Star Ratings quence of the HRM measure would be pine sedative hypnotic medications using 2013 claims data. Both mea- increased use of benzodiazepines for are defined to include estazolam, 32 America’s PHARMACIST | January 2015 temazepam, triazolam, flurazepam, them frequently over a prolonged peri- use of the benzodiazepine agents spe- and quazepam.
    [Show full text]
  • Quality Use of Medicines in Residential Aged Care
    RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Drug Class Review on Newer Sedative Hypnotics
    Drug Class Review on Newer Sedative Hypnotics Final Report December 2005 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Susan Carson, MPH Po-Yin Yen, MS Marian S. McDonagh, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Final Report Drug Effectiveness Review Project TABLE OF CONTENTS Introduction....................................................................................................................... 4 Scope and Key Questions ............................................................................................. 4 Methods.............................................................................................................................. 6 Literature Search........................................................................................................... 6 Study Selection ............................................................................................................
    [Show full text]
  • Public Law 106-172 106Th Congress An
    PUBLIC LAW 106-172—FEB. 18, 2000 114 STAT. 7 Public Law 106-172 106th Congress An Act To amend the Controlled Substances Act to direct the^ emergency scheduling of gamma hydroxybutyric acid, to provide for a national awareness campaign, and Feb. 18, 2000 for other piu"poses. [H.R. 2130] Be it enacted by the Senate and House of Representatives of the United States of America in Congress assewMed, Hillory J. Farias and Samantha SECTION 1. SHORT TITLE. Reid Date-Rape Drug Prohibition This Act may be cited as the "Hillory J. IFarias and Samantha Act of 2000. Reid Date-Rape Drug Prohibition Act of 2000". Law enforcement and crimes. SEC. 2. FINDINGS. 21 use 801 note. Congress finds as follows: 21 use 812 note. (1) Gamma hydroxybutyric acid (also called G, Liquid X, Liquid Ecstasy, Grievous Bodily Harm, Georgia Home Boy, Scoop) has become a significant and growing problem in law enforcement. At least 20 States have sclieduled such drug in their drug laws and law enforcement officials have been experi­ encing an increased presence of the dinig in driving under the influence, sexual assault, and overdose cases especially at night clubs and parties. (2) A behavioral depressant and a hypnotic, gamma hydroxybutyric acid ("GHB") is being used in conjunction with alcohol and other drugs with detrimental effects in an increasing number of cases. It is difficult to isolate the impact of such drug's ingestion since it is so typically taken with an ever-changing array of other drugs £md especially alcohol which potentiates its impact. (3) GHB takes the same path as alcohol, processes via alcohol dehydrogenase, and its symptoms at high levels of intake and as impact builds are comparable to alcohol inges- i- tion/intoxication.
    [Show full text]
  • PHRP March 2015
    March 2015; Vol. 25(2):e2521518 doi: http://dx.doi.org/10.17061/phrp2521518 www.phrp.com.au Research Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study Danijela Gnjidica,b,i, Sallie-Anne Pearsona,c, Sarah N Hilmerb,d, Jim Basilakise, Andrea L Schaffera, Fiona M Blythb,f,g and Emily Banksg,h, on behalf of the High Risk Prescribing Investigators a Faculty of Pharmacy, University of Sydney, NSW, Australia b Sydney Medical School, University of Sydney, NSW, Australia c Sydney School of Public Health, University of Sydney, NSW, Australia d Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia e School of Computing, Engineering and Mathematics, University of Western Sydney, NSW, Australia f Centre for Education and Research on Ageing (CERA), Concord Hospital, Sydney, NSW, Australia g The Sax Institute, Sydney, NSW, Australia h National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT i Corresponding author: [email protected] Article history Abstract Publication date: March 2015 Background: Increasingly, automated methods are being used to code free- Citation: Gnjidic D, Pearson S, Hilmer S, text medication data, but evidence on the validity of these methods is limited. Basilakis J, Schaffer AL, Blyth FM, Banks E. To examine the accuracy of automated coding of previously keyed Manual versus automated coding of free-text Aim: in free-text medication data compared with manual coding of original self-reported medication data in the 45 and Up Study: a validation study. Public Health handwritten free-text responses (the ‘gold standard’).
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Plant Powers, Poisons, and Herb Craft
    PLANT POWERS, POISONS, AND HERB CRAFT BY DALE PENDELL Foreword by Gary Snyde, $21.95 US In 'Pharmako/Poeia, Dale Pendell offers a mesmerizing guide to psychoactive Alternative plants, from their pharmacological roots to the literary offshoots. "This is a Health/ book," writes Gary Snyder, "about danger: dangerous knowledge, even more Literature dangerous ignorance." Against the greater danger, ignorance, Pendell strikes a formidable blow, as he proves himself a wise and witty guide to our plant teach- ers, their powers and their poisons. "Dale Pendell reactivates the ancient connection between the bardic poet and the shaman. His Pharmako/Poeia is a litany to the secret plant allies that have always accompanied us along the alchemical trajectory that leads to a new and yet authentically archaic future." — Terence McKenna, author of True Hallucinations "Much of our life-force calls upon the plant world for support, in medicines and in foods, as both allies and teachers. Pendell provides a beautifully crafted bridge between these two worlds. The magic he shares is that the voices are spoken and heard both ways; we communicate with plants and they with us. This book is a moving and poetic presentation of this dialogue." — Dr. Alexander T. Shulgin, University of California at Berkeley, Department of Public Health "Pharmako/Poeia is an epic poem on plant humours, an abstruse alchemic treatise, an experiential narrative jigsaw puzzle, a hip and learned wild-nature reference text, a comic paean to cosmic consciousness, an ecological handbook, a dried-herb pastiche, a countercultural encyclopedia of ancient fact and lore that cuts through the present 'conservative' war-on-drugs psychobabble." - Allen Ginsberg, poet Cover design "Dale PendelFs remarkable book will make it impossible to and color work ever again underestimate the most unprepossessing plant.
    [Show full text]
  • Insomnia in Adults
    New Guideline February 2017 The AASM has published a new clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. These new recommendations are based on a systematic review of the literature on individual drugs commonly used to treat insomnia, and were developed using the GRADE methodology. The recommendations in this guideline define principles of practice that should meet the needs of most adult patients, when pharmacologic treatment of chronic insomnia is indicated. The clinical practice guideline is an essential update to the clinical guideline document: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. SPECIAL ARTICLE Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults Sharon Schutte-Rodin, M.D.1; Lauren Broch, Ph.D.2; Daniel Buysse, M.D.3; Cynthia Dorsey, Ph.D.4; Michael Sateia, M.D.5 1Penn Sleep Centers, Philadelphia, PA; 2Good Samaritan Hospital, Suffern, NY; 3UPMC Sleep Medicine Center, Pittsburgh, PA; 4SleepHealth Centers, Bedford, MA; 5Dartmouth-Hitchcock Medical Center, Lebanon, NH Insomnia is the most prevalent sleep disorder in the general popula- and disease management of chronic adult insomnia, using existing tion, and is commonly encountered in medical practices. Insomnia is evidence-based insomnia practice parameters where available, and defined as the subjective perception of difficulty with sleep initiation, consensus-based recommendations to bridge areas where such pa- duration, consolidation, or quality that occurs despite adequate oppor- rameters do not exist.
    [Show full text]